Objective. The purpose of this study was to evaluate the clinical efficacy of apatinib plus concurrent radiotherapy on carcinoma embryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression in patients with non-small-cell lung cancer (NSCLC) with oligometastases. Methods. This is a prospective randomized controlled trial. Sixty-four patients with oligometastatic NSCLC who were treated in the Central South University Xiangya School of Medicine Affiliated Haikou Hospital from January 2017 to January 2019 were randomly assigned into the control group and the study group, with 32 cases in each group. The control group was treated with stereotactic body radiotherapy (SBRT), and the study group was treated with apatinib. Results. The overall response rate (ORR) of the study group was significantly higher than that of the control group. The carcinoma embryonic antigen (CEA) and the vascular endothelial growth factor (VEGF) in the two groups were significantly decreased, with lower results in the study group compared to the control group. The 12-month and 24-month overall survival (OS) of the study group were significantly higher than those of the control group. There was no significant difference in progression-free survival (PFS) between the two groups. The median OS in the control group was 20.0 months, and the study group had not yet reached the median OS; the OS in the study group was significantly higher than that in the control group. There was no significant difference in adverse reactions between the two groups. Conclusion. For patients with oligometastatic lung cancer, apatinib combined with chemotherapy can significantly improve clinical efficacy, reduce tumor marker expression, and extend overall survival with good safety profiles.

We attempt to study the short-term and long-term efficacy and safety of pemetrexed combined with tislelizumab in advanced epidermal growth factor receptor tumor protein 53 co-variant lung adenocarcinoma. The purpose is to explore the application effect of chemotherapy combined with immunotherapy in advanced epidermal growth factor receptor tumor protein 53 co-variant lung adenocarcinoma and provides reference for clinical work. We randomly selected 66 patients with advanced epidermal growth factor receptor+tumor protein 53 co-variant lung adenocarcinoma received from July 2019 to June 2021, then divided them into control group (n=33) and observation group (n=33). Treated control group with chemotherapy alone (pemetrexed), treated observation group chemotherapy combined with immunotherapy (pemetrexed+tislelizumab). Evaluated the short-term and long-term efficacy and safety of both groups, and checked the changes of immune indexes before and after treatment in both groups. In the comparison of short-term efficacy, observation group had higher disease control rate and objective remission rate than control group (p<0.05); but in the comparison of long-term efficacy, observation group had remarkably higher median disease progression-free survival than control group (p<0.05); both groups had no obvious difference in adverse reactions rate (p>0.05); in the comparison of immune indicators, observation group had higher cluster of differentiation 3 + , cluster of differentiation 4 + , cluster of differentiation 4 + /cluster of differentiation 8 + and natural killer cells activities in T cell subsets than control group, but lower cluster of differentiation 8 + in T cell subgroup than control group (p<0.05). Chemotherapy combined with immunotherapy (pemetrexe+tislelizumab) application is effective and safe in advanced epidermal growth factor receptor+tumor protein 53 co-variant lung adenocarcinoma treatment, can prolong the survival period of patients, has good safety and will not have a great impact on immune indicators level.

Li et al.: Efficacy of Tislelizumab with Carboplatin/Cisplatin Pemetrexed in Lung AdenocarcinomaWe attempt to study the short-term efficacy of tislelizumab+carboplatin/cisplatin+pemetrexed in advanced lung adenocarcinoma and its effect on tumor markers. Retrospectively analyzed the clinical data of 68 advanced lung adenocarcinoma patients admitted to our hospital from May 2019 to June 2021 and divided them into control group (n=34) and study group (n=34). Treated control group with carboplatin or cisplatin+pemetrexed, while treated study group with tislelizumab+carboplatin or cisplatin+pemetrexed. Compared both groups on total clinical response rate, serum tumor marker levels and immune function indexes before treatment and after 6 mo treatment. Study group had higher total effective rate than control group (p<0.05); after 6 mo treatment, study group had lower serum carbohydrate antigen 125, carbohydrate antigen 199 and carcinoembryonic antigen levels than control group (p<0.05). Meanwhile, study group had higher cluster of differentiation 3, cluster of differentiation 4 and cluster of differentiation 4/cluster of differentiation 8 than control group, while lower cluster of differentiation 8 than control group (p<0.05). Tislelizumab plus carboplatin or cisplatin plus pemetrexed therapy in advanced lung adenocarcinoma can improve short-term efficacy, reduce serum tumor marker levels and improve immune function.

No abstract